FY2017 Earnings Forecast for Alnylam Pharmaceuticals, Inc. (ALNY) Issued By Jefferies Group

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) – Stock analysts at Jefferies Group upped their FY2017 earnings per share estimates for shares of Alnylam Pharmaceuticals in a report issued on Monday. Jefferies Group analyst M. Raycroft now expects that the biopharmaceutical company will earn ($5.39) per share for the year, up from their previous forecast of ($5.49). Jefferies Group currently has a “Buy” rating and a $130.00 price target on the stock. Jefferies Group also issued estimates for Alnylam Pharmaceuticals’ Q4 2017 earnings at ($1.32) EPS, FY2018 earnings at ($5.70) EPS, FY2019 earnings at ($3.91) EPS, FY2020 earnings at ($1.71) EPS and FY2021 earnings at $1.41 EPS.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($1.34) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($1.23) by ($0.11). The business had revenue of $17.10 million during the quarter, compared to the consensus estimate of $28.15 million. Alnylam Pharmaceuticals had a negative return on equity of 46.94% and a negative net margin of 664.70%. The company’s revenue for the quarter was up 24.8% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($1.21) earnings per share.

A number of other equities research analysts also recently weighed in on the company. Piper Jaffray Companies reiterated a “buy” rating and issued a $182.00 target price on shares of Alnylam Pharmaceuticals in a report on Sunday. B. Riley reiterated a “buy” rating and issued a $205.00 target price (down from $220.00) on shares of Alnylam Pharmaceuticals in a report on Monday. Goldman Sachs Group upgraded Alnylam Pharmaceuticals from a “buy” rating to a “conviction-buy” rating in a report on Friday, December 15th. BidaskClub downgraded Alnylam Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, December 7th. Finally, Cowen reiterated a “buy” rating and issued a $151.00 target price on shares of Alnylam Pharmaceuticals in a report on Thursday, November 9th. Three investment analysts have rated the stock with a sell rating, seven have assigned a hold rating, fifteen have assigned a buy rating and one has assigned a strong buy rating to the stock. Alnylam Pharmaceuticals presently has a consensus rating of “Buy” and a consensus target price of $121.20.

Shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) opened at $128.60 on Wednesday. The firm has a market capitalization of $12,650.00, a P/E ratio of -24.50 and a beta of 2.98. The company has a quick ratio of 9.83, a current ratio of 9.83 and a debt-to-equity ratio of 0.14. Alnylam Pharmaceuticals has a 1-year low of $35.98 and a 1-year high of $147.63.

A number of hedge funds have recently bought and sold shares of the business. Public Employees Retirement System of Ohio boosted its position in Alnylam Pharmaceuticals by 3.2% in the third quarter. Public Employees Retirement System of Ohio now owns 32,880 shares of the biopharmaceutical company’s stock worth $3,863,000 after purchasing an additional 1,026 shares during the last quarter. Security National Bank of SO Dak purchased a new position in Alnylam Pharmaceuticals in the third quarter worth $247,000. California Public Employees Retirement System boosted its position in Alnylam Pharmaceuticals by 5.1% in the third quarter. California Public Employees Retirement System now owns 133,206 shares of the biopharmaceutical company’s stock worth $15,650,000 after purchasing an additional 6,506 shares during the last quarter. Virtu Financial LLC purchased a new position in Alnylam Pharmaceuticals in the third quarter worth $286,000. Finally, Orbimed Advisors LLC boosted its position in Alnylam Pharmaceuticals by 69.7% in the third quarter. Orbimed Advisors LLC now owns 1,084,800 shares of the biopharmaceutical company’s stock worth $127,453,000 after purchasing an additional 445,600 shares during the last quarter. 88.39% of the stock is currently owned by institutional investors and hedge funds.

In related news, Director Dennis A. Ausiello sold 20,000 shares of the company’s stock in a transaction on Thursday, November 2nd. The stock was sold at an average price of $130.00, for a total transaction of $2,600,000.00. Following the completion of the sale, the director now owns 20,000 shares in the company, valued at $2,600,000. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, EVP Akshay Vaishnaw sold 33,666 shares of the company’s stock in a transaction on Monday, October 30th. The stock was sold at an average price of $121.46, for a total value of $4,089,072.36. Following the sale, the executive vice president now owns 45,201 shares of the company’s stock, valued at approximately $5,490,113.46. The disclosure for this sale can be found here. Insiders have sold 274,075 shares of company stock valued at $35,356,089 in the last quarter. 4.30% of the stock is currently owned by corporate insiders.

COPYRIGHT VIOLATION NOTICE: “FY2017 Earnings Forecast for Alnylam Pharmaceuticals, Inc. (ALNY) Issued By Jefferies Group” was reported by Community Financial News and is owned by of Community Financial News. If you are viewing this story on another publication, it was illegally copied and republished in violation of U.S. & international copyright & trademark law. The legal version of this story can be viewed at https://www.com-unik.info/2018/01/11/fy2017-earnings-forecast-for-alnylam-pharmaceuticals-inc-alny-issued-by-jefferies-group.html.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).

Earnings History and Estimates for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit